• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

PharmaJet begins enrollment for needle-free COVID-19 vaccine trial

June 30, 2021 By Sean Whooley

PharmaJetPharmaJet announced today that it began enrollment for a Phase 1 clinical trial for its needle-free COVID-19 vaccine in Australia.

Golden, Colo.-based PharmaJet’s needle-free injection systems will be studied with Covigen, a DNA-based vaccine developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with Melbourne, Australia-based Technovalia.

According to a news release, PharmaJet’s system was chosen for its record of increasing the effectiveness of DNA vaccines, ease of use and the speed of the delivery system when compared to traditional needles and syringes.

PharmaJet develops the Stratis system, which has FDA 510(k) clearance and CE mark to deliver medications and vaccines either intramuscularly or subcutaneously, as well as the Tropis system, which has CE mark for intradermal injections. The company touts its platforms as capable of eliminating needlestick injuries, needle reuse and cross-contamination while reducing sharps waste disposal.

The University of Sydney Children’s Hospital Westmead Clinical School associate professor and lead principal investigator Nicholas Wood said in the release that the PharmaJet system “is pivotal for the delivery into the skin or muscle,” making it key for putting the genetic code from the vaccine into the cells.

“We are pleased to be collaborating with BioNet-Asia and their partners as they begin their clinical trials,” PharmaJet president & CEO Chris Cappello said in the release. “Our needle-free systems are proven to generate an equal or superior immune response, as well as improve both the patient and caregiver experience.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, PharmaJet

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS